Ibis Therapeutics is Biotechnology in United States that focus on developer business. Founded in 2016. They cover business area such as developer, a drug discovery technology, therapeutic potency, an AI-base drug discovery tool, an idea, expect toxicity, both human and viral protein, certain property, antiviral testing, drug therapist, new drug, its technology, a less time, traditional approach, month, year.
2016
( 8 years old in 2024 )
Developer
-
USF Connect Building
3802 Spectrum Boulevard, Suite 155
Tampa, FL 33612
United States
Private
developera drug discovery technologytherapeutic potencyan AI-base drug discovery toolan ideaexpect toxicityboth human and viral proteincertain propertyantiviral testingdrug therapistnew drugits technologya less timetraditional approachmonthyear
* We use standard office opening hours in near Ibis Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ibis Therapeutics is Biotechnology business from United States that founded in 2016 (8 years old in 2024), Ibis Therapeutics business is focusing on Developer.
Ibis Therapeutics headquarter office and corporate office address is located in USF Connect Building 3802 Spectrum Boulevard, Suite 155 Tampa, FL 33612 United States.
Ibis Therapeutics was founded in United States.
In 2024, Ibis Therapeutics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ibis Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
